BEAM
BEAM INC COM STK (DE)BEAM
BEAM
Delisted
BEAM was delisted on the 30th of April, 2014.
Financial journalist opinion
Negative
Investors Business Daily
3 days ago
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.
Positive
Seeking Alpha
3 days ago
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases
Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from phase 1/2 BEACON study using BEAM-101, expected in the 2nd half of 2025. The global sickle cell disease market is expected to reach $12.38 billion by 2032.
Neutral
GlobeNewsWire
1 week ago
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Positive
Zacks Investment Research
2 weeks ago
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Neutral
Zacks Investment Research
2 weeks ago
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.
Neutral
GlobeNewsWire
3 weeks ago
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).
Neutral
GlobeNewsWire
3 weeks ago
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effective therapies that can treat the entire spectrum of disease.
Neutral
GlobeNewsWire
1 month ago
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101
Neutral
GlobeNewsWire
1 month ago
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 11:00 a.m.
Neutral
GlobeNewsWire
1 month ago
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effective therapies that can treat the entire spectrum of disease.
Charts implemented using Lightweight Charts™